```
ANSWER 10 OF 33 CAPLUS COPYRIGHT 2010 ACS on STN
     AN
DN
     137:185514
     Preparation of chromene derivatives for treatment and prevention of
ΤI
     retinopathy and diabetic retinopathy
     Fujita, Takashi; Oguchi, Minoru; Yokoyama, Tomihisa; Inoue, Tatsuya
IN
     Sankyo Company, Limited, Japan
PΑ
     PCT Int. Appl., 245 pp.
SO
     CODEN: PIXXD2
DT
     Patent
LA
     Japanese
FAN.CNT 1
                                                                 DATE
                        KIND
                               DATE
                                           APPLICATION NO.
     PATENT NO.
                                           -----
                        ____
                               ------
                               20020829
                                          WO 2002-JP1501
                                                                 20020220 <--
PT
     WO 2002066454
                         A1
        W: AU, BR, CA, CN, CO, CZ, HU, ID, IL, IN, KR, MX, NO, NZ, PH, PL, RU, SG, SK, US, VN, ZA
         RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL,
             PT, SE, TR
                                                                 20020220 <--
                               20020904
                                           AU 2002-234893
     AU 2002234893
                         A1
                               20021108
                                           JP 2002-42721
                                                                 20020220 <--
                         Α
     JP 2002322169
                               20010221
PRAI JP 2001-45256
                         Α
                               20020220
     WO 2002-JP1501
                         W
     MARPAT 137:185514
OS
GI
```

AB The title compds. I [R1 represents hydrogen, optionally substituted C1-6 alkyl, C6-10 aryl, or C1-12 acyl; R2, R3, R4, and R5 are the same or different and each represents hydrogen, halogeno, C1-6 alkyl, C3-6 cycloalkyl, etc.; R6 represents hydrogen, halogeno, optionally substituted C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, etc.; R7 and R8 are the same or different and each represents hydrogen, halogeno, C1-6 alkyl, C3-6 cycloalkyl, optionally substituted C6-10 aryl, or an optionally substituted five- to ten-membered heterocyclic group; the dotted line indicates a double bond or a single bond; and Ar represents optionally substituted C6-10 aryl or an optionally substituted five- to ten-membered heterocyclic group] are prepared. In an in vitro test, the antiproliferative activity of 16 compds. of this invention was ≥ 30 times that of the known translast. Formulations are given.

IT 452075-21-7P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES

(Uses) (preparation of chromene derivs. for treatment and prevention of

(preparation of chromene derivs. for treatment and prevention of retinopathy

and diabetic retinopathy)

RN 452075-21-7 CAPLUS

CN 2H-1-Benzopyran-3-carboxamide, 6-(acetyloxy)-5,7,8-trimethyl-N-[2-[[[(tetrahydro-2H-pyran-2-yl)oxy]amino]carbonyl]phenyl]- (CA INDEX NAME)

IT 452077-19-9P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of chromene derivs. for treatment and prevention of retinopathy

and diabetic retinopathy)

RN 452077-19-9 CAPLUS

CN 2H-1-Benzopyran-3-carboxamide, 6-(acetyloxy)-5,7,8-trimethyl-N-[2-[[(phenylmethoxy)amino]carbonyl]phenyl]- (CA INDEX NAME)

OSC.G 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (1 CITINGS)
RE.CNT 84 THERE ARE 84 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT